Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NCT06536010
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
Sponsor
Yang Xiaotian